Female Health Co. (NASDAQ:FHCO)

CAPS Rating: 5 out of 5

The Female Health Company engages in the manufacture, marketing, and distribution of the female condom.

Results 1 - 20 of 63 : 1 2 3 4 Next »

Recs

0
Member Avatar AtomicBlicky (21.69) Submitted: 7/17/2014 11:24:23 AM : Outperform Start Price: $4.08 FHCO Score: -2.30

Use these and less people will exist to have temper tantrums!~

Recs

0
Member Avatar 2good2betrue (< 20) Submitted: 7/16/2014 10:17:56 AM : Outperform Start Price: $4.28 FHCO Score: -6.26

Just following tenmiles on this one - under 10 PE with growing dividend.

Recs

3
Member Avatar TMFTypeoh (81.61) Submitted: 7/15/2014 12:45:43 PM : Outperform Start Price: $4.20 FHCO Score: -5.01

Two days have been pounding this stock, as the company went from a small cap dividend payer to a small cap growth stock only. Divindend investors are dumping like crazy. At $4.20, the stock is selling a a P/E under 10. Considering their market opportunity, a small position could prove to be a long term good move.

Recs

0
Member Avatar TMFbuild (36.58) Submitted: 7/8/2014 3:19:06 PM : Outperform Start Price: $5.68 FHCO Score: -29.53

The Business moat: For sexually active couples, condom is the only barrier method approved by FDA for preventing sexual transmission of HIV/AIDs.

About FHCO: The company manufactures and sells FC2 condoms. They are the only female condoms approved by FDA and cleared by WHO for purchase by UN agencies. The company’s primary customers are large global agencies such as UNFPA, USAID. The current focus of the firm has been to distribute its product through agencies rather than tapping clients directly. Indirectly, the prime customers are the developing countries where the chances of STIs are high and product’s accessibility is quite low. These agencies distribute the condoms directly to these people.

The Company’s moat: FC2’s classification as a Class III medical device creates a significant barrier to entry in the US market for other players. As per the company’s estimation, it usually takes a minimum of 4-6 years to launch another FDA approved condom. The right set of chord with government agencies and a good product quality has helped FHCO win big tenders.

Recs

0
Member Avatar AnsgarJohn (99.24) Submitted: 6/23/2014 7:12:07 PM : Outperform Start Price: $5.51 FHCO Score: -27.79

http://www.gurufocus.com/insider/FHCO Female Condoms, via Niek Kraakman

Recs

0
Member Avatar JPlace09 (21.81) Submitted: 5/4/2014 5:55:49 PM : Outperform Start Price: $7.26 FHCO Score: -49.32

Great ethical Stock for my portfolio.

Recs

0
Member Avatar roguer (< 20) Submitted: 3/10/2014 10:22:34 AM : Outperform Start Price: $7.03 FHCO Score: -47.37

sell the female condom. distributed abroad. massive free cash flow.

Recs

3
Member Avatar ValuePicksOnly (84.06) Submitted: 2/12/2014 2:39:03 AM : Outperform Start Price: $6.67 FHCO Score: -47.33

The price of FHCO is in decline since their last earnings release. What people seem to forget, and what FHCO management is constantly repeating, is that their income fluctuates immensely due to the spending patterns of governments and NGO's. Despite lower reported earnings there is NO decrease in demand, it is just the cycle.

I therefore see this as an amazing opportunity to make us of irrational behavior by investors. This company has a tremendously strong balance sheet. My intrinsic value estimate is $12.

Recs

0
Member Avatar shrutisDad (52.22) Submitted: 12/6/2013 3:13:28 PM : Outperform Start Price: $8.91 FHCO Score: -62.89

Under-valued, near-monopoly

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:35:50 PM : Outperform Start Price: $8.67 FHCO Score: -69.03

Long. 14x fye. 21% rev growth. Female condoms.

Recs

0
Member Avatar mainiac5800 (< 20) Submitted: 5/25/2013 8:43:32 PM : Outperform Start Price: $8.78 FHCO Score: -71.07

Management owns a big slice of the pie, here. They keep voting themselves new dividends. Sales of female condoms are increasing in the developing world.

Recs

0
Member Avatar leglamp (47.09) Submitted: 4/23/2013 7:33:53 PM : Outperform Start Price: $7.27 FHCO Score: -68.58

This company has a great yield, low P/E and is solving a global problem.

Recs

0
Member Avatar BGPenhollo (52.06) Submitted: 4/3/2013 8:32:42 PM : Outperform Start Price: $7.07 FHCO Score: -68.94

Low debt, unique and needed product, unbelievable ROI. reasonable to low PE, and it pays a dividend with a payout of less than 50%. It's a no-brainer for me.

Recs

1
Member Avatar AlexeiVronsky (90.87) Submitted: 3/23/2013 12:32:00 AM : Outperform Start Price: $6.48 FHCO Score: -63.39

Seems to be a fundamentally sound company, though the reliance on government and NGO income means I won't be adding it to my portfolio.

Recs

1
Member Avatar BKITU (95.08) Submitted: 3/12/2013 11:31:31 AM : Outperform Start Price: $6.58 FHCO Score: -64.78

Decent financials, consumable product, lots of growth potential not only in industrializing countries, but in already-industrialized countries. That's a rare treat these days.

Recs

0
Member Avatar FutureMonkey (82.89) Submitted: 3/2/2013 2:53:31 PM : Outperform Start Price: $6.91 FHCO Score: -70.63

Top 25 best company pick

Recs

0
Member Avatar s123entler (< 20) Submitted: 3/1/2013 1:28:46 PM : Outperform Start Price: $6.90 FHCO Score: -70.30

There is a defintie need for theior producct which will continue for quite a while.

Recs

0
Member Avatar AStarSearch (55.67) Submitted: 2/11/2013 10:50:55 PM : Outperform Start Price: $7.14 FHCO Score: -76.68

underdeveloped nations need this

Recs

0
Member Avatar mitleg (< 20) Submitted: 1/12/2013 4:58:28 PM : Outperform Start Price: $7.14 FHCO Score: -76.68

This has been a steady performer, bit it is still cheap. It also helps to have a product that is revolutionary.

Recs

0
Member Avatar WakeUpInvestor (23.07) Submitted: 1/4/2013 7:10:55 PM : Outperform Start Price: $7.01 FHCO Score: -76.58

During the London Summit in 2012, the Female Health Company announced a program to support the London Summit's goal to provide contraceptives to an additional 120 million women by 2020. This program includes a plan for the company to invest up to $14 million over the next six years in reproductive health and HIV/AIDS prevention education and training in collaboration with global agencies.

Results 1 - 20 of 63 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement